Polymorphism effects

Sagar, M., et al., "Omeprazole and CYP2C19 Polymorphism Effects of Long-Term Treatment on Gastrin, Pepsinogen I, and Chromogranin A in Patients with Acid Related Disorders," Aliment. Pharmacol. Then, 14, 1495-1502 (2000). [Pg.186]

Transporter Drug polymorphic effects Reference variabihty Reference... [Pg.56]

Polymorphism Amino acid change in enzyme Population prevalence of polymorphism (%) Effect of polymorphism on enzyme activity Biochemical effect of polymorphism Clinical effects Reference... [Pg.423]

Polymorphism Effect of polymorphism Biochemical changes associated with SSZ therapy Clinical effects Reference... [Pg.425]

Zheng YF (1993a) Oxygen isotope fractionation in Si02 and Al2Si05 polymorphs effect of crystal structure. Eur J Miner 5 651-658... [Pg.280]

R. A. S. (2003). Functional analysis of the fibrinogen AaThr312Ala polymorphism Effects on fibrin structure and function. Circulation 107, 2326-2330. [Pg.296]

Nebert, D.W., R.A. McKinnon, and A. Puga. 1996. Human drug-metabolizing enzyme polymorphisms Effects on risk of toxicity and cancer. DNA Cell Biol. 15(4) 273-280. [Pg.222]

Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-a promoter polymorphism effects transcription. Molecular Immunol. 1997, 34 391-399. [Pg.170]

Hein, D. W. IV-Acetyltransferase 2 genetic polymorphism Effects of carcinogen and haplo-type on urinary bladder cancer risk. Oncogene 25, 1649-1658, 2006. [Pg.256]

Polymorphism Effect of Polymorphism Possible Pathological Associations... [Pg.177]

Costa, L.G., Cole, T.B., Jarvik, G.P., Furlong, C.E. (2003). Functional genomic of the paraoxonase (PONl) polymorphisms effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Anna. Rev. Med. 54 371-92. [Pg.709]

Mamiya, K., Hadama, A., Yukawa, E., Ieiri, I., Otsubo, K., Ninomiya, H., Tashiro, N., and Higuchi, S. CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy Analysis by population pharmacokinetics. European Journal of Clinical Pharmacology 2000 55 821-825. [Pg.375]

Dresser M (2001). The MDRl C3434T polymorphism effects on P-glycoprotein expression/function and clinical significance. AAPS Pharm Sci3 Commentary 3 1-3, http //www.aapspharmsci.org. Giacomini KM et al. (2007). The Pharmacogenetics Research Network from SNP discovery to clinical drug response. Clin Pharmacol Ther 81 328-345. [Pg.388]

Azuma J, Hasunuma T, Kubo M, Miyatake M, Koue T, Higashi K, et al. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. Eur J Clin Pharmacol 2012 68(l) 29-/37. [Pg.79]

Wang, C., Liao, W-P., Cheng, Y-W. Strong diffuse scattering and lamellar morphologies of syndiotactic polystyrene Polymorphic effects. J. Polym. Sci. Part B Polym. Phys., 41,2457-2469 (2003). [Pg.190]

In 1965, Walter C. McCrone introduced the term pseudo-polymorphism [ 18]. By his definition, pseudo-polymorphic effects included desolvation/dehydration products, second-order transitions and dynamic isomerism however, today the term is generally limited to all phenomena connected with solvates and hydrates. Any substance used in the pharmaceutical industry has the ability to form so-called crystalline hydrates or solvates. In these structures, volatiles (either water or solvent) are not only physisorbed at the solid-air interface but also incorporated into the crystal lattice structure (chemisorbed) as a guest molecule, either in stoichiometric or in non-stoichiometric amounts. Careful consideration must be... [Pg.303]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...